RESUMO
Pain assessment in patients with disorders of consciousness (DoC) is a controversial issue for clinicians, who require tools and standardised procedures for testing nociception in non-communicative patients. The aims of the present study were, first, to analyse the psychometric properties of the Italian version of the Nociception Coma Scale and, second, to evaluate pressure pain thresholds in a group of patients with DoC. The authors conducted a multi-centre study on 40 healthy participants and 60 DoC patients enrolled from six hospitals in Italy. For each group an electronic algometer was used to apply all nociceptive pressure stimuli. Our results show that the Italian version of the NCS retains the good psychometric properties of the original version and is therefore suitable for standardised pain assessment in clinical practice. In our study, pressure pain thresholds measured in a group of patients in vegetative and minimally conscious state were relatively lower than pain threshold values found in a group of healthy participants. Such findings motivate additional investigation on possible pain sensitisation in patients with severe brain injury and multiple co-morbidities, and on application of tailored therapeutic approaches useful for pain management in patients unable verbally to communicate their feelings.
Assuntos
Transtornos da Consciência/diagnóstico , Transtornos da Consciência/fisiopatologia , Medição da Dor , Limiar da Dor , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dor Nociceptiva/diagnóstico , Dor Nociceptiva/fisiopatologia , Variações Dependentes do Observador , Pressão , Psicometria , Sensibilidade e EspecificidadeRESUMO
Given the importance of adrenergic neural functioning in cardiovascular control, the hypothesis that an elevation in sympathetic drive represents a key pathophysiological feature of diseases characterized by an impairment in cardiac or renal function has been long considered. However, modern approaches to directly quantify sympathetic nerve firing in humans have only been possible in the last 2 decades to provide objective documentation for the hypothesis. This paper will review the evidence that conditions such as essential hypertension, congestive heart failure and metabolic syndrome are all accompanied by an increased sympathetic drive, which is likely in all of them to play a pathogenetic role. It will then offer examples showing that sympathetic influences are directly involved in the progression of organ damage associated with these conditions. Finally, evidence will be presented that a maximum degree of sympathetic activation can be seen in end-stage renal failure, in which a relationship between sympathetic activation and clinical outcome has been documented. This has therapeutic implications, which involve the need to use treatments that oppose rather than enhance sympathetic neural activation.
Assuntos
Doenças Cardiovasculares/fisiopatologia , Nefropatias/fisiopatologia , Sistema Nervoso Simpático/fisiologia , Doenças Cardiovasculares/tratamento farmacológico , Humanos , Nefropatias/tratamento farmacológico , Sistema Nervoso Simpático/efeitos dos fármacos , Simpatolíticos/uso terapêuticoRESUMO
OBJECTIVE: Screening and educational campaigns on cardiovascular (CV) risk factors are important for primary and secondary prevention of CV disease. The CardioLab project is an observational cross-sectional study aimed at determining the prevalence of CV risk factors in a large unselected sample of the Italian population leaving in northern, central and southern Italy. METHODS AND RESULTS: Data collection included family and clinical history, anthropometric data, blood pressure, blood glucose and total cholesterol values. Individual CV risk profile was assessed throughout by the risk charts of both the Progetto Cuore and the Score Project. In 36,161 participants (56.3% men) with a mean age of 60 years a complete assessment of the above mentioned variables was obtained. 44.4% of the screened subjects was overweight, while approximately 20% of the population displayed an obese state with a body mass index >30 kg/m2. Alterations in blood glucose levels indicating the presence of glucose intolerance were identified in 11.5% of the population while 9.3% displayed overt diabetes. 36.1% and 42.3% had elevated total cholesterol levels (> 200 mg/dl) and blood pressure values (> or = 140/90 mmHg), respectively. New diagnosis of diabetes, hypercholesterolaemia and hypertension was obtained in 5.3%, 23.6% and 19.6%, respectively. Global assessment of the CV risk showed that approximately 12.6% of the population is at a high risk of CV events over a 10-year period. CONCLUSIONS: This large-scale observational study provides important information on the CV risk profile of an unselected Italian population and underlines the need for a more aggressive identification and appropriate correction of CV risk factors.
Assuntos
Doenças Cardiovasculares/epidemiologia , Nível de Saúde , Idoso , Estudos Transversais , Diabetes Mellitus/epidemiologia , Feminino , Intolerância à Glucose/epidemiologia , Humanos , Hipercolesterolemia/epidemiologia , Hiperglicemia/epidemiologia , Hipertensão/epidemiologia , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Medição de Risco , Fatores de RiscoRESUMO
OBJECTIVE: Previous studies have shown that heart rate has a limited value in reflecting the chronic state of adrenergic overdrive characterizing several cardiovascular diseases. Whether this also applies to the ability of heart rate to reflect acute and generalized changes in sympathetic activity is unknown. METHODS: In 20 healthy young subjects (age: 25.2 +/- 1.2 years, mean +/- SEM) we measured beat-to-beat blood pressure (Finapres), heart rate (HR, ECG), venous plasma norepinephrine (NE, high-performance liquid chromatography) and efferent postganglionic muscle sympathetic nerve traffic (MSNA, microneurography) at rest and during a cold pressor test and two intravenous infusions of nitroprusside at increasing doses. RESULTS: Both cold pressor test and nitroprusside infusions triggered marked and significant increases in HR, plasma NE and MSNA; blood pressure showing an increase with cold pressor test and a reduction with nitroprusside. The magnitude of the responses was greater with the higher than with the lower dose of nitroprusside. The HR changes induced by cold pressor test were not significantly related to the concomitant NE and MSNA changes (r = -0.08 and r = -0.18, P = NS). This was also the case for the lower and the higher dose of nitroprusside (NE: r = -0.11 and r = 0.08; MSNA: r = 0.01 and r = -0.11, P = NS for all). In contrast NE and MSNA changes induced by cold pressor test and by the lower and the higher dose of nitroprusside were significantly related to each other (r = 0.70, r = 0.89 and r = 0.79 respectively, P < 0.01 for all). CONCLUSIONS: In a given individual, HR responses to sympathetic challenge do not quantitatively reflect the degree of acute and generalized adrenergic activation. Qualitative information on the acute adrenergic effects of given stimuli should thus be based on the assessment of NE and MSNA rather than on HR changes.
Assuntos
Temperatura Baixa , Frequência Cardíaca/fisiologia , Sistema Nervoso Simpático/fisiologia , Adulto , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Relação Dose-Resposta a Droga , Feminino , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Humanos , Infusões Intravenosas , Masculino , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/fisiologia , Nitroprussiato/administração & dosagem , Norepinefrina/sangue , Valores de Referência , Reprodutibilidade dos Testes , Descanso/fisiologia , Sistema Nervoso Simpático/efeitos dos fármacosRESUMO
OBJECTIVE: To assess the reproducibility of the two markers of adrenergic drive, venous plasma norepinephrine (NE) and efferent postganglionic muscle sympathetic nerve activity (MSNA), in reflecting the sympathetic activation characterizing congestive heart failure (CHF). METHODS AND MEASUREMENTS: In 19 CHF male normotensive patients (mean age: 53.0+/-2.1 years, NYHA classes II and III, left ventricular ejection fraction 35.9+/-2.9%), blood pressure (BP, Finapres), heart rate (EKG), plasma NE (HPLC assay) and MSNA (microneurography, peroneal nerve) were measured in two experimental sessions separated by a week interval. At each session, three NE samples were obtained and NE reproducibility between sessions was assessed by considering single NE samples or averaging 2-3 samples. RESULTS: While MSNA values showed a highly significant correlation between sessions (r=0.85, P<0.001), NE values based on a single blood sample evaluation did not correlate with each other (r=0.41, P=NS). NE correlation coefficients improved and achieved statistical significance when average data from 2 and 3 blood samples were examined (r=0.54 and r=0.57, P<0.02 for both). CONCLUSIONS: In CHF, MSNA displays a better reproducibility pattern than plasma NE. The reproducibility of the NE approach, however, can be improved by performing the assay on multiple blood samples.
Assuntos
Insuficiência Cardíaca/fisiopatologia , Norepinefrina/sangue , Fibras Simpáticas Pós-Ganglionares/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Biomarcadores , Insuficiência Cardíaca/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Estatística como Assunto , Volume Sistólico , Função Ventricular EsquerdaRESUMO
Direct and indirect indices of neuroadrenergic function have shown that end-stage renal disease is characterized by a marked sympathetic overdrive. It is unknown, however, whether this phenomenon represents a peculiar feature of end-stage renal disease or whether it is also detectable in the early clinical phases of the disease. The study has been performed in 73 hypertensive patients, of which there were 42 (age: 60.7±1.8 years, mean±SEM) with a stable moderate chronic renal failure (mean estimated glomerular filtration rate: 40.7 mL/min per 1.73 m2, MDRD formula) and 31 age-matched controls with a preserved renal function. Measurements included anthropometric variables, sphygmomanometric and beat-to-beat blood pressure, heart rate (ECG), venous plasma norepinephrine (high-performance liquid chromatography), and efferent postganglionic muscle sympathetic nerve activity (microneurography, peroneal nerve). For similar anthropometric and hemodynamic values, renal failure patients displayed muscle sympathetic nerve activity values significantly and markedly greater than controls (60.0±2.1 versus 45.7±2.0 bursts per 100 heartbeats; P<0.001). Muscle sympathetic nerve activity showed a progressive and significant increase from the first to the fourth quartile of the estimated glomerular filtration rate values (first: 41.0±2.7; second: 51.9±1.7; third: 59.8±3.0; fourth: 61.9±3.3 bursts per 100 heartbeats), the statistical significance (P<0.05) between groups being maintained after adjustment for confounders. In the population as a whole, muscle sympathetic nerve activity was significantly and inversely correlated with the estimated glomerular filtration rate (r=-0.59; P<0.0001). Thus, adrenergic activation is a phenomenon not confined to advanced renal failure but already detectable in the initial phases of the disease. The sympathetic overdrive parallels the severity of the renal failure, state and, thus, it might participate, in conjunction with other factors, at the disease progression.
Assuntos
Hipertensão/fisiopatologia , Falência Renal Crônica/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Adulto , Idoso , Barorreflexo/fisiologia , Pressão Sanguínea/fisiologia , Cromatografia Líquida de Alta Pressão , Eletrocardiografia , Feminino , Frequência Cardíaca/fisiologia , Humanos , Hipertensão/sangue , Hipertensão/complicações , Falência Renal Crônica/sangue , Falência Renal Crônica/complicações , Masculino , Pessoa de Meia-Idade , Norepinefrina/sangueRESUMO
OBJECTIVES: We compared definitions of metabolic syndrome performed by ATPIII [the National Cholesterol Education Program Adult Treatment Panel III; three criteria of the following: systolic blood pressure >or=130 mmHg and/or diastolic blood pressure >or=85 mmHg, fasting serum glucose >or=110 mg/dl, high-density lipoprotein plasma cholesterol
Assuntos
Doenças Cardiovasculares/etiologia , Síndrome Metabólica/complicações , Síndrome Metabólica/diagnóstico , Adulto , Idoso , Glicemia/metabolismo , Pressão Sanguínea , Doenças Cardiovasculares/mortalidade , HDL-Colesterol/sangue , Diabetes Mellitus/etiologia , Feminino , Humanos , Hipertensão/etiologia , Hipertrofia Ventricular Esquerda/etiologia , Gordura Intra-Abdominal/patologia , Itália/epidemiologia , Estimativa de Kaplan-Meier , Estudos Longitudinais , Masculino , Síndrome Metabólica/patologia , Síndrome Metabólica/fisiopatologia , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Fatores de Risco , Circunferência da CinturaRESUMO
Alterations in glucose and lipid metabolism frequently cluster with overweight, obesity as well as hypertension in the clinical condition known as metabolic syndrome. The "cardiometabolic clustering" is characterized by well-known alterations that increase cardiovascular risk profile such as insulin-resistance, endothelial dysfunction, arterial stiffening, cardiac hypertrophy, and sympathetic activation. The present article will review the evidence collected throughout by years that an increase in the different markers of adrenergic drive, such as plasma norepinephrine and muscle sympathetic nerve traffic, characterizes this condition. Frequently, the increase also involves heart rate, as documented by the results of different epidemiological studies, such as the Pressioni Arteriose Monitorate E Loro Associazioni, in which an increase in heart rate has been shown in patients with metabolic syndrome, in which this hemodynamic parameter has been assessed in the doctor's office, at home, or during the 24-hour period. Finally, current findings suggest that in metabolic syndrome heart rate displays a significant correlation with other indirect and direct adrenergic markers. Taken together, these findings reinforce the concept that drugs used in the metabolic syndrome should exert sympathoinhibitory effects.
Assuntos
Frequência Cardíaca/fisiologia , Hipertensão/fisiopatologia , Síndrome Metabólica/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Anti-Hipertensivos/farmacologia , Anti-Hipertensivos/uso terapêutico , Catecolaminas/sangue , Endotélio/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/tratamento farmacológico , Norepinefrina/sangueRESUMO
The sympathetic overdrive that characterizes essential hypertension is potentiated when left ventricular hypertrophy or congestive heart failure is detected. No information exists, however, on whether this is the case also for left ventricular diastolic dysfunction. In 17 untreated hypertensive subjects with left ventricular diastolic dysfunction (age: 47.7+/-2.9 years, mean+/-SEM), we measured sympathetic nerve traffic (microneurography), heart rate (ECG), and beat-to-beat arterial blood pressure (Finapres) at rest and during baroreceptor deactivation and stimulation. Data were compared with those collected in 20 age-matched normotensive and 20 hypertensive subjects without a diastolic function impairment. Muscle sympathetic nerve traffic values were markedly and significantly greater in the 2 hypertensive groups than in the normotensive one (55.3+/-1.2 and 71.2+/-1.6 versus 41.7+/-1.0 bursts per 100 heartbeats, respectively; P<0.01 for both). For a similar blood pressure elevation, however, the sympathetic nerve traffic increase was significantly greater in patients with than without left ventricular diastolic dysfunction (+28.9%; P<0.05). In the population as a whole, muscle sympathetic nerve traffic was significantly and inversely related to various echocardiographic indices of diastolic function. Although baroreflex-heart rate control was significantly attenuated in the 2 hypertensive groups, baroreflex-sympathetic modulation was impaired only in those with diastolic dysfunction. These data provide the first evidence that, in hypertension, activation of the sympathetic nervous system may contribute not only at the blood pressure elevation but also at the development of left ventricular diastolic dysfunction. The sympathetic overactivity, which is likely to be related to the baroreflex impairment, may account for the increased cardiovascular risk characterizing diastolic dysfunction.
Assuntos
Barorreflexo/fisiologia , Fenômenos Fisiológicos Cardiovasculares , Hipertensão/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Disfunção Ventricular Esquerda/fisiopatologia , Adulto , Pressão Sanguínea/fisiologia , Débito Cardíaco/fisiologia , Estudos de Casos e Controles , Ecocardiografia Doppler , Frequência Cardíaca/fisiologia , Ventrículos do Coração/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Volume Sistólico/fisiologia , Disfunção Ventricular Esquerda/diagnóstico por imagemRESUMO
OBJECTIVES: Chronic renal failure is characterized by a marked sympathetic activation. No information exists, however, as to whether the adrenergic overdrive is confined to selected vascular districts or is rather generalized to the whole cardiovascular system. METHODS: In 15 patients aged 60.5 +/- 2.0 years (mean +/- SEM) with stable chronic renal failure belonging to stage 2-3 of the Kidney Foundation classification and in 12 age-matched healthy controls, we measured arterial blood pressure (Finapres), heart rate (ECG), venous plasma norepinephrine (high-performance liquid chromatography) and postganglionic sympathetic nerve traffic in skeletal muscle and skin areas (microneurography). Muscle and skin nerve traffic measurements were made in a randomized sequence over two periods of 30 min each, spaced by a 20-30-min interval. Measurements also included evaluation of skin sympathetic responses to emotional stimuli. RESULTS: Muscle sympathetic nerve traffic was markedly and significantly greater in renal failure patients compared with controls (58.2 +/- 3.6 vs. 36.8 +/- 5.7 bursts/100 heart beats, P < 0.01), with this also being the case for plasma norepinephrine (380.6 +/- 63 vs. 210.8 +/- 29 pg/ml, P < 0.05). By contrast, skin sympathetic nerve traffic was superimposable in the two groups (11.5 +/- 0.8 vs. 12.7 +/- 1.7 bursts/minute, P = not significant), this being the case also for the responses to emotional arousal. CONCLUSION: These data provide the first evidence that the sympathetic activation characterizing renal failure is not generalized to the entire cardiovascular system. This may depend on the fact that the two sympathetic districts are governed by mechanisms that are differently affected by the chronic uraemic state.
Assuntos
Falência Renal Crônica/fisiopatologia , Músculo Esquelético/inervação , Pele/inervação , Sistema Nervoso Simpático/fisiologia , Adulto , Idoso , Nível de Alerta/fisiologia , Pressão Sanguínea/fisiologia , Determinação da Pressão Arterial/métodos , Diástole/fisiologia , Eletrocardiografia , Feminino , Frequência Cardíaca/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Norepinefrina/sangue , Volume Sistólico , Vasoconstritores/sangue , Disfunção Ventricular Esquerda/fisiopatologiaRESUMO
OBJECTIVES: Previous studies have shown that left ventricular hypertrophy (LVH) represents a cardiovascular risk factor independently of clinic blood pressure (BP). The present study was aimed at determining the impact of LVH on the incidence of cardiovascular morbid and fatal events taking into account not only classical risk factors but also home and ambulatory BP values, which have been shown to have an important independent prognostic impact. METHODS: In 1716 patients belonging to the 'Pressioni Arteriose Monitorate E Loro Associazioni' population of Monza, we quantified left ventricular mass index and identified LVH by standard cutoff values. We also measured clinic, home and 24-h ambulatory BPs together with serum glucose and lipids. RESULTS: During a follow-up of 148 months, the rate of fatal and nonfatal (hospitalizations) cardiovascular events as well as of all-cause death was markedly greater (four-fold to five-fold) in patients as compared with those without LVH. In LVH individuals, the increased risk remained significant even when data were adjusted for a large number of other confounding factors including home BP, 24-h mean BP and ambulatory BP. Results were similar when left ventricular mass was indexed by height and body surface area. A 10% increase in left ventricular mass index was associated with a significant increase in cardiovascular risk or all-cause deaths. In multivariate analysis, left ventricular mass index was always an independent predictor of cardiovascular events and death for any cause. CONCLUSION: Our data provide evidence that LVH is an important risk factor even when the contribution of different BPs to risk is fully taken into account.
Assuntos
Pressão Sanguínea , Doenças Cardiovasculares/fisiopatologia , Hipertensão/fisiopatologia , Hipertrofia Ventricular Esquerda/fisiopatologia , Adulto , Idoso , Determinação da Pressão Arterial , Monitorização Ambulatorial da Pressão Arterial , Doenças Cardiovasculares/mortalidade , Comorbidade , Feminino , Humanos , Hipertensão/mortalidade , Hipertrofia Ventricular Esquerda/mortalidade , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Visita a Consultório Médico , Fatores de Risco , Taxa de SobrevidaRESUMO
High blood pressure represents one of the leading risk factors for the development of stroke and its recurrence. This explains why blood pressure control is a major objective of antihypertensive treatment, both in primary and secondary prevention of this cerebrovascular disease. This paper reviews the evidence provided by randomized clinical trials on the favorable effects exerted by blood pressure reduction on this end point. Emphasis is given to the results of recently published clinical trials documenting that drugs acting on the renin-angiotensin system may exert cerebrovascular protective effects additive to the ones associated with blood pressure reduction.
Assuntos
Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Prevenção Primária/métodos , Acidente Vascular Cerebral/prevenção & controle , Ensaios Clínicos como Assunto , Humanos , Hipertensão/complicações , Hipertensão/fisiopatologia , Fatores de Risco , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/fisiopatologiaRESUMO
Patients with hypertension exhibit an increased sympathetic activity. No information exists as to whether this is the case in normotensive individuals in whom there is an increased ambulatory blood pressure, a condition termed "masked" hypertension. We studied 18 middle-aged subjects with masked hypertension in whom we measured muscle sympathetic nerve traffic (peroneal nerve and microneurography) and beat-to-beat arterial blood pressure at rest and during baroreceptor deactivation and activation. Measurements also included anthropometric values and insulin sensitivity (homeostasis model assessment index). Data were compared with those of 20 normotensive subjects, 18 subjects with white-coat hypertension, and 20 patients with "in-office" and "out-of-office" hypertension. All of the individuals were pharmacologically untreated and age-matched with subjects with masked hypertension. Patients with in- and out-of-office and white-coat hypertension displayed resting sympathetic nerve activity values significantly greater than normotensive subjects (75.8+/-2.5 and 70.8+/-2.2 versus 45.5+/-2.0 bursts per 100 heartbeats respectively; P<0.01). This was the case also for masked hypertension (73.5+/-2.4 bursts per 100 heartbeats; P<0.01), the degree of the sympathetic activation being similar for magnitude to that seen in the other 2 hypertensive conditions. Compared with normotensive subjects, baroreflex-heart rate control was significantly attenuated in all of the hypertensive states, whereas baroreflex-sympathetic control was unaffected. Homeostasis model assessment index was increased in patients with in- and out-of-office and white-coat hypertension, with a further increase in masked hypertension and a direct relation with resting sympathetic nerve traffic (r=0.46; P<0.01). These data provide the first evidence that masked hypertension is characterized by a marked sympathetic overdrive. They further show that the neurogenic alterations are coupled with metabolic and baroreflex abnormalities.
Assuntos
Monitorização Ambulatorial da Pressão Arterial , Hipertensão/diagnóstico , Hipertensão/fisiopatologia , Sistema Nervoso Simpático/fisiopatologia , Barorreflexo , Pressão Sanguínea , Feminino , Frequência Cardíaca , Homeostase , Humanos , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , Nervo Fibular/fisiopatologiaRESUMO
No agreement exists as to the mechanisms responsible for the sympathetic hyperactivity characterizing human obesity, which has been ascribed recently to a chemoreflex stimulation brought about by obstructive sleep apnea rather than to an increase in body weight, per se. In 86 middle-age normotensive subjects classified according to body mass index, waist-to-hip ratio, and apnea/hypopnea index (overnight polysomnographic evaluation) as lean and obese subjects without or with obstructive sleep apnea, we assessed via microneurography muscle sympathetic nerve traffic. The 4 groups were matched for age, gender, and blood pressure values, the 2 obese groups with and without obstructive sleep apnea showing a similar increase in body mass index (32.4 versus 32.0 kg/m2, respectively) and waist-to-hip ratio (0.96 versus 0.95, respectively) compared with the 2 lean groups with or without obstructive sleep apnea (body mass index 24.3 versus 23.8 kg/m2 and waist-to-hip ratio 0.77 versus 0.76, respectively; P<0.01). Compared with the nonobstructive sleep apnea lean group, muscle sympathetic nerve activity showed a similar increase in the obstructive sleep apnea lean group and in the nonobstructive sleep apnea obese group (60.4+/-2.3 and 59.3+/-2.0 versus 40.9+/-1.8 bs/100 hb, respectively; P<0.01), a further increase being detected in obstructive sleep apnea subjects (73.1+/-2.5 bursts/100 heart beats; P<0.01). Our data demonstrate that the sympathetic activation of obesity occurs independently in obstructive sleep apnea. They also show that this condition exerts sympathostimulating effects independent of body weight, and that the obstructive sleep apnea-dependent and -independent sympathostimulation contribute to the overall adrenergic activation of the obese state.